VJHemOnc is committed to improving our service to you

SOHO 2020 | CAR-T therapy for aggressive B-cell lymphomas

VJHemOnc is committed to improving our service to you

Peter A. Riedell

Peter A. Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses the use of CAR T-cell therapies for patients with aggressive B-cell lymphomas, including tisagenlecleucel and axicabtagene ciloleucel, both approved by the FDA in the third line setting for patients with aggressive B-cell lymphomas. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter